Freya Pharma Solutions Secures Us$8.5 Million Enabling The Start Of A Pivotal Phase 3 Trial With Lybrido Against Female Sexual Interest/Arousal Disorder (Fsiad)
Freya Pharma Solutions Secures Us$8.5 Million Enabling The Start Of A Pivotal Phase 3 Trial With Lybrido Against Female Sexual Interest/Arousal Disorder (Fsiad)
03/29/22, 3:00 AM
Location
Money raised
$8.5 million
Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been diagnosed with Female Sexual Interest/Arousal Disorder (FSIAD), today announced to have secured US$8.5 million in new funding from existing and new investors. The new funding will be used to carry out a pivotal phase 3 trial with its therapy Lybrido in 516 patients across Europe. Previously, Lybrido showed clinical relevance and statistical significance in a phase 2b clinical trial, clearly meeting the primary endpoints. The phase 3 trial will start in the second half of 2022, with interim results expected by the second half of 2023.
Company Info
Location
amsterdam, new york, united states
Additional Info
Freya Pharma Solutions is a late clinical stage company focused on developing effective pharmaceutical therapies for female sexual interest/arousal disorder (FSIAD), building upon fifteen years of solid research. The company has two compounds in development, Lybrido and Lybridos, to address the range of potential causes of FSIAD. Based in Amsterdam, The Netherlands, Freya aims to offer patients a convenient, personalized 'on demand' solution for this recognized unmet medical need.